Microperimetry could provide extra info on macula function

Microperimetry may provide additional information on macula function that is not available using visual acuity data.

Microperimetry may provide additional information on macula function that is not available using visual acuity data, according to a study in Retina.

A team led by Dr M. Parravano, Fondazione G.B. Bietti-IRCCS, Rome, Italy, evaluated 18 neovascular AMD patients in a retrospective 24-week follow-up study. All patients received three injections of ranibizumab 0.5 mg one month apart and were retreated according to predefined criteria.

Baseline measurements included visual acuity, fluorescein angiography, microperimetry and optical coherence tomography stratus. Measurements for visual acuity, microperimetry and OCT evaluations were also conducted 28 days after each injection.

Mean retinal sensitivity significantly improved from a baseline of 3.89 ± 3.0 dB to 6.61 ± 3.4 dB at 24 weeks. Mean visual acuity improved from 48.67 ± 8.58 to 60.72 ± 16.09, with 44.4% of patients gaining 15 letters or more and 38.9% gaining a mean of 6.14 ± 3.7 letters. However, 16.7% of patients lost a mean of 7.3 ± 2.1 letters.

Fixation stability improved from baseline in 33.3% of patients and central macula thickness significantly decreased from 310.5 ± 85.7 µ to 217.3 ± 46.8 µ at 24 weeks.

Overall, visual acuity and retinal thickness changes appeared to peak at four weeks after the administration of intravitreal ranibizumab 0.5 mg. Retinal sensitivity measured by microperimetry presented a trend of progressive improvement until 24 weeks.

To read the abstract please click here.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.